Novel immunostimulating peptides
AssigneeAimvion A/S
InventorShervin Bahrami
Life of this patent
Estimating the term…
Abstract
The invention provides for novel immunostimulating peptides, peptide constructs and compositions. Further, the invention provides for methods of treatment utilising the peptides, peptide constructs and compositions.
Claims42
A peptide consisting of or comprising a sequence variant of the amino acid sequence LQNRRGLGLSILLNEEC (SEQ ID NO:
- 1), wherein the sequence variant comprises at least one amino acid change compared to SEQ ID NO:
- 1, and wherein the peptide stimulates secretion and/or expression of cytokines when supplied in an effective concentration to THP-1 cells or PBMCs stimulated with lipopolysaccharide (LPS).
30-37. (canceled)
40-41. (canceled)
A method for prophylactic or therapeutic treatment of a disease, wherein said treatment comprises co-administration of a prophylactically or therapeutically active amount of
- a peptide according to claim 1 and
- an immunogen
- so as to enhance, stimulate or elicit a specific adaptive immune response against the immunogen in a subject in need thereof. 43. A method for preparation of antibodies that specifically binds an immunogen, the method comprising co-administration to an animal of an immunogenically active amount of
- a peptide according to claim 1, and
- the immunogen,
- so as to effect production of antibodies specific for said immunogen in said animal, and subsequently recovering said antibodies from the animal. 44. The method according to claim 42, wherein the co-administration is accomplished by administering the peptide, the peptide construct, the conjugate molecule, or the pharmaceutical composition, and the immunogen either as part of one pharmaceutical composition or as parts of separate compositions that are administered within a time interval that allows the peptide, the peptide construct, the conjugate molecule, or the pharmaceutical composition to enhance the immune response against the immunogen 45. The method according to claim 42, wherein the peptide, the peptide construct, the conjugate molecule, or the pharmaceutical composition acts as an immunologic adjuvant.
The method according to claim 43, wherein the co-administration is accomplished by administering the peptide, the peptide construct, the conjugate molecule, or the pharmaceutical composition, and the immunogen either as part of one pharmaceutical composition or as parts of separate compositions that are administered within a time interval that allows the peptide, the peptide construct, the conjugate molecule, or the pharmaceutical composition to enhance the immune response against the immunogen.
Dependencies are inferred from the claim text.